Sivik Global Healthcare LLC Purchases 6,500 Shares of Insulet Co. (NASDAQ:PODD)

Sivik Global Healthcare LLC increased its position in shares of Insulet Co. (NASDAQ:PODD) by 32.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,500 shares of the medical instruments supplier’s stock after purchasing an additional 6,500 shares during the period. Insulet makes up about 2.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 23rd biggest holding. Sivik Global Healthcare LLC’s holdings in Insulet were worth $5,750,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. AE Wealth Management LLC increased its holdings in shares of Insulet by 332.0% during the third quarter. AE Wealth Management LLC now owns 3,784 shares of the medical instruments supplier’s stock worth $604,000 after purchasing an additional 2,908 shares during the period. Czech National Bank raised its holdings in Insulet by 47.9% in the 3rd quarter. Czech National Bank now owns 12,203 shares of the medical instruments supplier’s stock valued at $1,946,000 after acquiring an additional 3,953 shares in the last quarter. Asset Management One Co. Ltd. lifted its position in shares of Insulet by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 27,437 shares of the medical instruments supplier’s stock valued at $4,376,000 after acquiring an additional 647 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in shares of Insulet by 18.2% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,024 shares of the medical instruments supplier’s stock valued at $482,000 after acquiring an additional 466 shares during the period. Finally, Xponance Inc. increased its position in shares of Insulet by 6.0% in the third quarter. Xponance Inc. now owns 16,812 shares of the medical instruments supplier’s stock worth $2,681,000 after purchasing an additional 949 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PODD. Barclays cut their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Stifel Nicolaus upped their target price on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Piper Sandler decreased their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Finally, JPMorgan Chase & Co. upped their price objective on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Insulet Trading Up 1.0 %

NASDAQ PODD traded up $1.68 on Tuesday, hitting $171.94. The company’s stock had a trading volume of 758,586 shares, compared to its average volume of 857,969. The firm has a market cap of $12.04 billion, a PE ratio of 59.09, a PEG ratio of 2.99 and a beta of 0.98. The company’s 50-day moving average is $171.09 and its 200 day moving average is $180.25. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period in the previous year, the business earned $0.55 EPS. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. As a group, analysts predict that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.